Synergistic Treatment Systems for Congenital Diarrheal Disorders
Legal Citation
Summary of the Inventive Concept
The present invention combines proanthocyanidin polymer compositions with advanced technologies, such as AI, IoT, blockchain, and nanomaterials, to create a more effective and personalized treatment system for congenital diarrhea disorders.
Background and Problem Solved
Congenital Diarrheal Disorders (CDDs) are a group of inherited chronic enteropathies characterized by heterogeneous etiology. The original patent addressed the need for effective treatments using proanthocyanidin polymer compositions. However, the current invention takes a significant leap forward by integrating these compositions with cutting-edge technologies to provide a more comprehensive and adaptive treatment approach.
Detailed Description of the Inventive Concept
The inventive concept comprises four main components: 1) a proanthocyanidin polymer composition, 2) an artificial intelligence module for monitoring and adjusting dosage, 3) a blockchain-secured platform for genomic data analysis and personalized treatment planning, and 4) a nanomaterial-based delivery system for targeted enterocyte treatment. Additionally, the system may include IoT-enabled wearable devices for remote monitoring and machine learning algorithms for data integration and optimization.
Novelty and Inventive Step
The new claims introduce a synergistic combination of proanthocyanidin polymer compositions with AI, IoT, blockchain, and nanomaterials, which provides a non-obvious and innovative solution for treating congenital diarrhea disorders. The integration of these technologies enables real-time monitoring, personalized treatment, and targeted delivery, significantly improving treatment outcomes.
Alternative Embodiments and Variations
Alternative embodiments may include varying the type of nanomaterial used, incorporating additional data sources into the machine learning algorithm, or using different blockchain platforms for secure data storage. Variations may also include adapting the system for use in different disease indications or integrating with existing electronic health record systems.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the areas of rare genetic disorders and personalized medicine. The system's ability to provide real-time monitoring and adaptive treatment plans makes it an attractive solution for healthcare providers and patients alike.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K31/353 |
| A | A61 | A61K9/0095 |
| A | A61 | A61K9/28 |
| A | A61 | A61K9/48 |
| A | A61 | A61P1/04 |
| A | A61 | A61P1/12 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Medical biotechnology focused on gastrointestinal disorder treatment, specifically congenital diarrheal disorders (CDD), with expertise in pharmaceutical composition design, drug delivery systems, and personalized medical technologies
Person of Ordinary Skill (PHOSITA) Profile
A professional with advanced degrees in biomedical engineering, pharmacology, or medical technology, possessing knowledge of pharmaceutical formulations, emerging medical technologies, data integration techniques, and personalized medicine approaches
Obviousness Rationale
A PHOSITA would recognize that integrating advanced digital technologies with existing pharmaceutical compositions represents a predictable extension of personalized medicine principles. The combination of proanthocyanidin polymer treatments with AI, blockchain, and nanomaterial delivery systems follows established technological convergence trends in medical treatment optimization. These technological augmentations provide incremental improvements that would be apparent to someone skilled in medical technology and pharmaceutical development.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,510 |
|---|---|
| Title | Methods and compositions for treating congenital diarrhea disorder |
| Assignee(s) | NAPO PHARMACEUTICALS, INC. |